Connect Biopharma Holdings Limited
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- Barry D. Quart
- Full Time Employees
- 64
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 3580 Carmel Mountain Road San Diego CA United States of America 92130
- IPO Date
- Mar 19, 2021
- CIK
- 0001835268
- Website
- connectbiopharma.com
- Similar Companies
- Business
- Connect Biopharma Holdings Limited (CNTB) is a clinical-stage global biopharmaceutical company focused on developing T cell-driven therapies for chronic inflammatory diseases, including asthma, atopic dermatitis, chronic rhinosinusitis with nasal polyps, ulcerative colitis, Crohn's disease, and pruritus; its pipeline features rademikibart (formerly CBP-201), a next-generation monoclonal antibody targeting interleukin-4 receptor alpha (IL-4Rα) to block IL-4 and IL-13 signaling, advancing in Phase 2 trials for acute exacerbations of asthma and chronic obstructive pulmonary disease (COPD) with topline data expected in the first half of 2026, Phase 3 asthma maintenance studies ongoing via partner Simcere in China where a New Drug Application for atopic dermatitis was submitted to the National Medical Products Administration in July 2025, and prior Phase 2/3 data in atopic dermatitis, asthma, and chronic rhinosinusitis; icanbelimod (formerly CBP-307), an oral small molecule sphingosine 1-phosphate receptor 1 (S1P1) modulator in Phase 2 for ulcerative colitis and Crohn's disease; and CBP-174, a peripherally acting histamine receptor 3 antagonist in early clinical development for pruritus in atopic dermatitis. Founded in 2012 and headquartered in San Diego, California, the company operates primarily in the United States with additional facilities in Taicang, Jiangsu Province, China, and South San Francisco, California, targeting patients with T cell-mediated inflammatory conditions through small molecules and antibodies discovered via proprietary functional T cell assays. Recent developments include leadership strengthening in 2024 with Barry Quart, Pharm.D., appointed as CEO and David Szekeres as President to enhance clinical, regulatory, and operational expertise; a strategic shift to a U.S.-centric focus with reduced China footprint and unveiled rapid development program for rademikibart in acute respiratory care; regained Nasdaq minimum bid price compliance; plans to terminate its American Depositary Receipt program and directly list ordinary shares on Nasdaq; presentations of supporting rademikibart data at the European Respiratory Society Congress 2025; and ongoing collaboration with Simcere for rademikibart commercialization in Greater China, generating minimal revenue of $64,000 year-to-date in 2025 amid elevated R&D costs for the asset.
Company News
Connect Biopharma Holdings Limited (CNTB) Discusses Topline Results of Rademikibart Phase 2 Study for Acute Asthma Exacerbations Transcript
Why Is Connect Biopharma Stock Trading Lower on Tuesday?
Connect Biopharma Announces Positive Preliminary Topline Data from its Global Phase 2 Study of Rademikibart as an Add-on Treatment for Acute Exacerbations in Adult and Adolescent Participants with Asthma and Type 2 Inflammation
Connect Biopharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Connect Biopharma Reports Second Quarter 2026 Financial Results and Provides Business Update
Brokerages Set Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Price Target at $7.29
Connect Biopharma: Attempting To Differentiate Rademikibart From Dupixent
Connect Biopharma Announces Completion of Enrollment of Phase 2 Seabreeze STAT Asthma Study Evaluating Rademikibart for the Treatment of Acute Exacerbations in Asthma
Connect Biopharma Touts Rademikibart's Edge as SEABREEZE Data Looms in 2026
Connect Biopharma to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference
Connect Biopharma Reports First Quarter 2026 Financial Results and Provides Business Update
Connect Biopharma: New Market Opportunity In The Emergency Setting
Connect Biopharma Announces Enrollment in Phase 2 Seabreeze STAT Studies Will Continue as Planned Following Pre-Specified Interim Analysis
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
Connect Biopharma Holdings Limited (CNTB) Discusses Phase 3 Atopic Dermatitis Study Results and Updates on Rademikibart Development Transcript
Connect Biopharma Announces $20.2 Million Private Placement Financing
Rademikibart Demonstrates Best-in-Class Potential in Phase 3 Atopic Dermatitis Study
Connect Biopharma Announces Positive Topline Data from its Phase 1 Study of Intravenous (IV) Rademikibart in Patients with Asthma or COPD
Connect Biopharma Holdings Limited Sponsored ADR (NASDAQ:CNTB) Given Consensus Recommendation of “Moderate Buy” by Brokerages
Results from Phase 3 Study of Rademikibart in Moderate-to-Severe Atopic Dermatitis to be Presented in the Late-Breaking Research Session at the 2026 American Academy of Dermatology (AAD) Annual Meeting